Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis
- V. J. Lipscomb, MA,VetMB, CertSAS, MRCVS1,
- M. J. Pead, BVetMed, PhD,CertSAO, MRCVS1,
- P. Muir, BVSc,MVetClinStud, PhD,DipACVS, DipECVS,MRCVS1,
- F. S. AliAbadi, DVetMed,PhD2 and
- P. Lees, BPharm, PhD, DSc,CBiol, FIBiol, Drhc(Gent),HonAssocRCVS, CBE2
- 1 Department of Small Animal Medicine and Surgery
- 2 Department of Veterinary Basic Sciences, The Royal Veterinary College, University of London, Hawkshead Campus, Hatfield, Herts AL9 7TA
- The University of Wisconsin-Madison, School of Veterinary Medicine, Department of Surgical Sciences, 2015 Linden Drive West, Madison, WI 53706, USA
Six medium to large breed dogs with osteoarthritis were treated with 2 mg/kg of racemic carprofen, mixed with their morning feed, daily for 28 days. The treatment significantly (P<0.01) reduced their mean lameness score, measured on a visual analogue scale, and there was a trend (P=0.1 1) for the peak vertical forces exerted on a forceplate to be increased in the most severely affected limb. The plasma concentration-time relationships of the S(+) and R(−) enantiomers were studied for 24 hours after the first dose and after seven days and 28 days. There were no significant differences between the mean pharmacokinetic parameters measured on the three occasions, suggesting that carprofen was not accumulated and that tolerance to the drug did not develop. Although the pharmacokinetic parameters of the S(+) and R(−) enantiomers were generally very similar, there were wide variations both between and within dogs.
- British Veterinary Association. All rights reserved.